

Revision date: 04-Sep-2013 Version: 2.0 Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Primor® (Sulfadimethoxine/Ormetoprim) Tablets

Trade Name: Primor® Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Veterinary product used as antimicrobial

Restrictions on Use: Not for human use

Details of the Supplier of the Safety Data Sheet

Zoetis Inc. 100 Campus Drive, P.O. Box 651 Florham Park, New Jersey 07932 (USA)

Rocky Mountain Poison Control Center Phone: 1-866-531-8896

Product Support/Technical Services Phone: 1-800-366-5288

Zoetis Belgium S.A. Mercuriusstraat 20 1930 Zaventem

Belgium

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: VMIPSrecords@zoetis.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Appearance: White to off-white cylindrical tablet

Classification of the Substance or Mixture

GHS - Classification

Skin Sensitization: Category 1

EU Classification:

EU Indication of danger: Irritant

EU Symbol: Xi

EU Risk Phrases:

R43 - May cause sensitization by skin contact.

Label Elements

Signal Word: Warning

Hazard Statements: H317 - May cause an allergic skin reaction

Precautionary Statements: P261 - Avoid breathing dust/fume/gas/mist/vapors/spray

P272 - Contaminated work clothing should not be allowed out of the workplace P280 - Wear protective gloves/protective clothing/eye protection/face protection

P302+ P352 - IF ON SKIN: Wash with plenty of soap and water

P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention

P362 - Take off contaminated clothing and wash before reuse

P501 - Dispose of contents/container in accordance with all local and national regulations

Material Name: Primor® (Sulfadimethoxine/Ormetoprim) Page 2 of 10

Tablets

Revision date: 04-Sep-2013 Version: 2.0



Other Hazards

Short Term: Contact with sulfonamides may cause dermatitis. Allergic skin reaction may occur based on

effects of other sulfonamides. Dust may cause irritation . Individuals sensitive to this chemical

or other materials in its chemical class may develop allergic reactions.

Known Clinical Effects: As in all sulfonamide therapy, the following reactions may occur including nausea, vomiting,

diarrhea, inflammation of the liver and pancreas, blood disorder, drug fever, skin rash, infection

of the conjunctiva and sclera, blood in the urine and crystalluria.

Australian Hazard Classification

(NOHSC):

Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU	EU Classification	GHS	%
		EINECS/ELINCS		Classification	
		List			
Corn Starch	9005-25-8	232-679-6	Not Listed	Not Listed	*
Starch, pregelatinized	9005-25-8	232-679-6	Not Listed	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	Not Listed	*
Microcrystalline cellulose	9004-34-6	232-674-9	Not Listed	Not Listed	*
Sulfadimethoxine	122-11-2	204-523-7	Xi;R43	Skin Sens. 1	59
				(H317)	
Ormetoprim	6981-18-6	230-246-6	Not Listed	Not Listed	11.8

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
FD&C blue No. 1 lake certified dye	NOT ASSIGNED	Not Listed	Not Listed	Not Listed	*
Sodium starch glycolate	9063-38-1	Not Listed	Not Listed	Not Listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

Material Name: Primor® (Sulfadimethoxine/Ormetoprim) Page 3 of 10

Tablets

Revision date: 04-Sep-2013 Version: 2.0

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get

medical attention.

Skin Contact: Remove contaminated clothing and shoes. Wash skin with soap and water. This material may

not be completely removed by conventional laundering. Consult professional laundry service.

Do not home launder. If irritation occurs or persists, get medical attention.

Ingestion: Get medical attention. Do not induce vomiting unless directed by medical personnel. Never

give anything by mouth to an unconscious person.

Inhalation: Remove to fresh air. If not breathing, give artificial respiration. Get medical attention.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Exposure: Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE-FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion May include oxide

Products:

May include oxides of carbon and sulfur

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Evacuate area and fight

fire from a safe distance.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning /

Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Additional Consideration for

Large Spills:

Collecting:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

Material Name: Primor® (Sulfadimethoxine/Ormetoprim) Page 4 of 10

Tablets

Revision date: 04-Sep-2013 Version: 2.0

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store in a cool, dry, well-ventilated area. Store as directed by product packaging.

Storage Temperature: 15-30°C (59-86°F)
Incompatible Materials: Strong oxidizers
Specific end use(s): No data available

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Corn Starch

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
OSHA - Final PELS - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL -TWAs	3 mg/m ³

Starch, pregelatinized

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
	4 mg/m ³
OSHA - Final PELS - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL -TWAs	3 mg/m ³

Material Name: Primor® (Sulfadimethoxine/Ormetoprim) Page 5 of 10

Tablets

Revision date: 04-Sep-2013 Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Magnesium stearate

10 mg/m³ **ACGIH Threshold Limit Value (TWA)** Lithuania OEL - TWA 5 mg/m³ Sweden OEL - TWAs 5 mg/m³

Microcrystalline cellulose

ACGIH Threshold Limit Value (TWA) 10 mg/m³ 10 mg/m³ **Australia TWA** 10 mg/m³ **Belgium OEL - TWA** 10 mg/m^3 **Estonia OEL - TWA** France OEL - TWA 10 mg/m³ Ireland OEL - TWAs 10 ma/m³ 4 mg/m³ Latvia OEL - TWA 2 mg/m^3 Vietnam O EL - TWAs 10 ma/m³ 5 mg/m³ 15 mg/m³ **OSHA - Final PELS - TWAs:** Portugal OEL - TWA 10 mg/m³ Spain OEL - TWA 10 mg/m³ Switzerland OEL -TWAs 3 mg/m³

Sulfadimethoxine

 0.1 mg/m^{3} Lithuania OEL - TWA

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Sulfadimethoxine

Zoetis OEB OEB 2 (control exposure to the range of 100ug/m³ to < 1000ug/m³)

Ormetoprim

OEB 2 (control exposure to the range of 100ug/m³ to < 1000ug/m³) Zoetis OEB

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep air contamination levels below the exposure limits or within the OEB range listed above in this

section.

Personal Protective Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE). **Equipment:**

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Wear safety glasses or goggles if eye contact is possible. Eyes:

Impervious protective clothing is recommended if skin contact with drug product is possible and Skin:

for bulk processing operations.

Whenever excessive air contamination (dust, mist, vapor) is generated, respiratory protection, Respiratory protection:

with appropriate protection factors, should be used to minimize exposure.

Material Name: Primor® (Sulfadimethoxine/Ormetoprim) Page 6 of 10

Tablets

Revision date: 04-Sep-2013 Version: 2.0

9. PHYSICAL AND CHEMICAL PROPERTIES

White to off-white **Physical State:** Cylindrical tablet Color: Odor: No data available. **Odor Threshold:** No data available.

Molecular Formula: Mixture **Molecular Weight:** Mixture

Solvent Solubility: No data available Water Solubility: No data available pH: No data available. Melting/Freezing Point (°C): No data available **Boiling Point (°C):** No data available. Partition Coefficient: (Method, pH, Endpoint, Value)

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available Vapor Pressure (kPa): No data available Vapor Density (g/ml): No data available No data available **Relative Density:** Viscosity: No data available

Flammablity:

Autoignition Temperature (Solid) (°C): No data available Flammability (Solids): No data available Flash Point (Liquid) (°C): No data available Upper Explosive Limits (Liquid) (% by Vol.): No data available Lower Explosive Limits (Liquid) (% by Vol.): No data available Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable

Possibility of Hazardous Reactions

Oxidizing Properties:

Conditions to Avoid: Direct sunlight, conditions that might generate heat and dispersion as a dust cloud

Incompatible Materials: Strong oxidizers **Hazardous Decomposition** No data available

Products:

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual

Acute Toxicity: (Species, Route, End Point, Dose)

Magnesium stearate

Oral LD50 Rat > 2000 mg/kg $> 2000 \text{ mg/m}^3$ Rat Inhalation LC50

Material Name: Primor® (Sulfadimethoxine/Ormetoprim) Page 7 of 10

Tablets

Revision date: 04-Sep-2013 Version: 2.0

11. TOXICOLOGICAL INFORMATION

Microcrystalline cellulose

Rat Oral LD50 > 5000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Ormetoprim

Oral LD50 665 mg/kg Rat Mouse Oral LD50 440mg/kg

Sulfadimethoxine

> 16 g/kgMouse Oral LD50 IΡ Mouse LD50 > 2g/kg Rat Oral LD50 > 10q/kq

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Inhalation Acute Toxicity Ingestion Acute Toxicity

No data available See Acute toxicity table.

Irritation / Sensitization: (Study Type, Species, Severity)

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Non-irritating

Ormetoprim

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Non-irritating

Skin Irritation / Sensitization

Dermatitis may occur from contact of sulfonamides with the skin. Hypersensitivity reactions to sulfonamides have been reported.

Chronic Effects/Carcinogenicity

Subchronic Effects

Studies to evaluate the carcinogenic potential of sulfadimethoxine and ormetoprim were not available. Other sulfonamide drugs which have been evaluated are not carcinogenic. Treatment of dogs with Primor (sulfadimethoxine/ormetoprim) at 27.5 mg/kg/day for eight weeks resulted in elevated serum cholesterol, increased thyroid and liver weights, enlarged basophilic cells in the pituitary and mild follicular thyroid hyperplasia. These changes are known to be associated with prolonged administration of sulfonamides to dogs and have been shown to be reversible. Dogs given daily oral doses of 160 mg/kg sulfadimethoxine for 13 weeks showed no signs of toxicity. In a 13-week study in dogs, ormetoprim at 60 mg/kg alone or in combination with 100 mg/kg sulfadimethoxine produced toxic reactions characterized by gastrointestinal disturbances and weight loss, brief seizures, hyperactivity and muscle tremors and salivation. Elevations in hematocrit and hemoglobin, indicative of dehydration, were also observed.

Reproductive Effects

Teratogenicity

Not determined

In humans, sulfonamides administered prior to delivery can cause jaundice and hemolytic anemia in the offspring. Studies in pregnant laboratory animals administered sulfadimethoxine

have shown developmental effects, but retrospective studies in humans with other

sulfonamides have not been conclusive.

Mutagenicity Other sulfonamide drugs which have been evaluated are not mutagenic.

Ormetoprim showed no evidence of mutagenic activity in bacterial or mammalian cell

assavs.

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Material Name: Primor® (Sulfadimethoxine/Ormetoprim) Page 8 of 10

Tablets

Revision date: 04-Sep-2013 Version: 2.0

11. TOXICOLOGICAL INFORMATION

At increase risk from exposure: Like other sulfonamides, this material can produce hypersensitivity reactions in some

individuals.

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to

the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications WHMIS hazard class:

Class D, Division 2, Subdivision B

Material Name: Primor® (Sulfadimethoxine/Ormetoprim) Page 9 of 10

Tablets

Revision date: 04-Sep-2013 Version: 2.0

15. REGULATORY INFORMATION

FD&C blue No. 1 lake certified dye

CERCLA/SARA 313 Emission reporting

California Proposition 65

EU EINECS/ELINCS List

Not Listed

Not Listed

Corn Starch

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Not Listed

Present

Present

Present

obligations of Register:

EU EINECS/ELINCS List 232-679-6

Sodium starch glycolate

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Starch, pregelatinized

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Present

Present

obligations of Register:

EU EINECS/ELINCS List 232-679-6

Magnesium stearate

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Present

Present

209-150-3

Microcrystalline cellulose

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not Listed

Present

232-674-9

045

Material Name: Primor® (Sulfadimethoxine/Ormetoprim) Page 10 of 10

Tablets

Revision date: 04-Sep-2013 Version: 2.0

15. REGULATORY INFORMATION

Sulfadimethoxine

CERCLA/SARA 313 Emission reporting

California Proposition 65

Australia (AICS):

Standard for the Uniform Scheduling

Not Listed

Not Listed

Present

Schedule 4

for Drugs and Poisons:

EU EINECS/ELINCS List 204-523-7

Ormetoprim

CERCLA/SARA 313 Emission reporting

California Proposition 65

EU EINECS/ELINCS List

Not Listed
230-246-6

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction

Xi - Irritant

R43 - May cause sensitization by skin contact.

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources,

raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 5 - Fire Fighting Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls

/ Personal Protection.

Prepared by: Toxicology and Hazard Communication

Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet